ALSO NOTED: Gloucester wins fast track; Cytos touts positive data; health officials probe drug reactions; and much more...

> Gloucester Pharmaceuticals has been granted Fast Track status for its novel histone deacetylase inhibitor, romidepsin, for the monotherapy of previously treated peripheral T-cell lymphoma. Release

> Switzerland's Cytos Biotechnology is reporting positive data from a Phase IIa trial of CYT003-QbG10, an immunotherapeutic product candidate for the treatment of allergic diseases. Release

> Metabolic Research has acquired the principal assets relating to metabolically engineered drug development, formulas, prototypes, packaging design and marketing rights from Partners in Science Holdings. The acquisition was completed through an "all stock" transaction. Release

> Japanese health officials are investigating a rash of reports of abnormal behavior among patients taking two anti-influenza medications. Report

> Jacobs Engineering Group has received a contract from Biogen Idec to provide engineering, procurement, validation, and site support services for the first cell culture manufacturing facility at the greenfield biotechnology plant in Hillerod, Denmark. Release

And Finally… A new study shows that the number of girls taking drugs for Type 2 diabetes tripled in five years while drug use for psychotic behavior and insomnia for boys and girls aged 10 to 19 doubled. Report

Suggested Articles

The clamor for more transparency from the leading pandemic vaccine contenders has been getting louder.

The role gives one of the driving forces behind Bristol Myers Squibb’s $74 billion takeover of Celgene the chance to help build biotechs.

The appointment gives Sino-American biotech Brii the experience of a man who helped Gilead launch eight drugs in China in quick succession.